Ask AI

Conference to Clinic: Integrating CD38-Based Quadruplet Therapy Into Care of Transplant-Ineligible and Transplant-Eligible NDMM

Enhance your understanding of anti-CD38 antibody-based quadruplet regimens for the management of newly diagnosed multiple myeloma. These therapies improve the care of transplant-ineligible, transplant-eligible, and underserved patients. Learn more through a certified on-demand webcast and accompanying downloadable slides.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme